Glofitamab in Real Life

NCT06994169 · tracked via the Priya Life Science France tracker

Sponsor

The Lymphoma Academic Research Organisation

Phase

Observational

Started

2025-12-01

Last updated

2026-06-03

Condition(s) studied

Large B-cell Lymphoma

Investigational drug(s) / intervention(s)

Glofitamab →

Glofitamab: Glofitamab received for DLBCL in Early Phase Access

Study summary

To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024 * patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab * adult patient * patient who is informed of the study and who did not oppose to their data collection Exclusion Criteria: * none

Primary outcome measure(s)

Best Complete Response Rate (best CRR) during treatment, assessed by investigator according to Lugano 2014 criteria. — 6 months

Trial sites (30)

Facility	City	Region	Status
CH Victor Dupouy	Argenteuil	France	Recruiting
CH d'Avignon - Hôpital Henri Dufaut	Avignon	France	Recruiting
CH de la Côte Basque	Bayonne	France	Recruiting
CHRU Besançon - Hôpital Minjoz	Besançon	France	Recruiting
Hopital D'Instruction Des Armees Percy	Clamart	France	Recruiting
Hopital Henri Mondor	Créteil	France	Recruiting
CHU de Dijon - Hôpital le Bocage	Dijon	France	Recruiting
CH de Dunkerque	Dunkirk	France	Recruiting
CHU de Grenoble - Hôpital Albert Michallon	La Tronche	France	Recruiting
Hôpital de Libourne	Libourne	France	Recruiting
CHRU de LILLE - Claude Huriez	Lille	France	Recruiting
Hopital Saint Vincent-de-Paul	Lille	France	Recruiting
Centre Léon Bérard	Lyon	France	Recruiting
INSTITUT PAOLI CALMETTES - Service Hématologie	Marseille	France	Recruiting
Clinique du Pont de Chaume	Montauban	France	Recruiting
CH de Mulhouse Sud Alsace	Mulhouse	France	Recruiting
CHR d'Orléans	Orléans	France	Recruiting
Hopital Saint-Louis	Paris	France	Recruiting
Chu de Bordeaux - Hopital Haut-Leveque	Pessac	France	Recruiting
CHU Lyon Sud	Pierre-Bénite	France	Recruiting
CHU de Poitiers - Hôpital de La Milétrie	Poitiers	France	Recruiting
CH de Quimper Cornouaille	Quimper	France	Recruiting
CHU de Rennes - Hôpital de Pontchaillou	Rennes	France	Recruiting
Institut Curie - Site Saint-Cloud	Saint-Cloud	France	Recruiting
CHU de Strasbourg	Strasbourg	France	Recruiting
Institut Universitaire du Cancer de Toulouse - Oncopole	Toulouse	France	Recruiting
Chu Bretonneau	Tours	France	Recruiting
CHRU de Nancy - Hôpital de Brabois	Vandœuvre-lès-Nancy	France	Recruiting
Ch de Bretagne Atlantique	Vannes	France	Recruiting
Gustave Roussy Cancer Campus Grand Paris	Villejuif	France	Recruiting

More The Lymphoma Academic Research Organisation trials in France

Study of Lacutamab in Peripheral T-cell Lymphoma Active, not recruiting

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma Recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 Active, not recruiting

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy Active, not recruiting

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T) Recruiting

Other trials for the same condition

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Active, not recruiting

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06994169 on ClinicalTrials.gov ↗ ← All trials in France